KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Mar 2025 value amounting to $7.7 million.

  • Supernus Pharmaceuticals' Gains from Investment Securities rose 194.16% to $7.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.2 million, marking a year-over-year increase of 21.75%. This contributed to the annual value of $53.3 million for FY2024, which is 45.49% up from last year.
  • As of Q1 2025, Supernus Pharmaceuticals' Gains from Investment Securities stood at $7.7 million, which was down 40.67% from $12.9 million recorded in Q4 2024.
  • In the past 5 years, Supernus Pharmaceuticals' Gains from Investment Securities registered a high of $12.9 million during Q4 2024, and its lowest value of -$8.8 million during Q2 2021.
  • In the last 3 years, Supernus Pharmaceuticals' Gains from Investment Securities had a median value of $2.6 million in 2023 and averaged $3.4 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Gains from Investment Securities skyrocketed by 1,978.48% in 2022, and later plummeted by 651.27% in 2024.
  • Supernus Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $79,000 in 2021, then soared by 1,978.48% to $1.6 million in 2022, then soared by 481.43% to $9.5 million in 2023, then spiked by 35.24% to $12.9 million in 2024, then soared by 194.16% to $7.7 million in 2025.
  • Its last three reported values are $7.7 million in Q1 2025, $12.9 million for Q4 2024, and -$1.0 million during Q3 2024.